CoChat

Multifunctional Au@AgBiS2 Nanoparticles as High‐Efficiency Radiosensitizers to Induce Pyroptosis for Cancer Radioimmunotherapy

Open access
Xiao, Liang, Chen, Benjin, Wang, Wanni, Tian, Tian, Qian, Haisheng, Li, Xiaohu, Yu, Yongqiang · 2023 · Advanced Science

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.

Abstract

Radiotherapy (RT), a widely used clinical treatment modality for cancer, uses high‐energy irradiation for reactive oxygen species (ROS) production and DNA damage. However, its therapeutic effect is primarily limited owing to insufficient DNA damage to tumors and harmful effects on normal tissues. Herein, a core‐shell structure of metal–semiconductors (Au@AgBiS 2 nanoparticles) that can function as pyroptosis inducers to both kill cancer cells directly and trigger a robust anti‐tumor immune against 4T1 triple‐negative murine breast cancer and metastasis is rationally designed. Metal‐semiconductor composites can enhance the generation of considerable ROS and simultaneously DNA damage for RT sensitization. Moreover, Au@AgBiS 2, a pyroptosis inducer, induces caspase‐3 protein activation, gasdermin E cleavage, and the release of damage‐associated molecular patterns. In vivo studies in BALB/c mice reveal that Au@AgBiS 2 nanoparticles combined with RT exhibit remarkable antitumor immune activity, preventing tumor growth, and lung metastasis. Therefore, this core‐shell structure is an alternative for designing highly effective radiosensitizers for radioimmunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/advs.202302141

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic illustration of Au@AgBiS2 ‐PEG design and anti‐tumor application. Descriptions provided for the indicated panels (A–C). The synthesis of multifunctional Au@AgBiS2 core‐shell structures using the intermediate layer conversion method (A). This composite exhibits the high efficacy as a radiosensitizer owing to the high level of ROS production and as an excellent pyroptosis inducer for boosting antitumor immunity (B) and effectively preventing lung metastasis (C).
Figure 1 Schematic illustration of Au@AgBiS2 ‐PEG design and anti‐tumor application. Descriptions provided for the indicated panels (A–C). The synthesis of multifunctional Au@AgBiS2 core‐shell structures using the intermediate layer conversion method (A). This composite exhibits the high efficacy as a radiosensitizer owing to the high level of ROS production and as an excellent pyroptosis inducer for boosting antitumor immunity (B) and effectively preventing lung metastasis (C).CC BY · PubMed Central
Figure 2 Synthesis, modification, and characterization of Au@AgBiS2. a) The synthesis process of the Au@AgBiS2. b–d) TEM images of the Au NRs, Au@ZnO, and Au@AgBiS2. e) HRTEM image of Au@AgBiS2. f–j) STEM images of Au@AgBiS2 and the elemental mappings of S, Bi, Au, and Ag, scale bars for g–j, 50 nm. k) UV–vis‐NIR absorbance spectra of Au, Au@AA‐[Zn(OH)4]2−, Au@ZnS, and Au@AgBiS2. l) XPS of the element peaks of Au@AgBiS2 and m) Bi 4f and S 2p peaks. n) XRD patterns of Au@AgBiS2. o) Zeta potentials and p) size distributions (n = 3) of Au@AgBiS2 and Au@AgBiS2‐PEG as determined by Malvern Zetasizer Nano ZS90.
Figure 2 Synthesis, modification, and characterization of Au@AgBiS2. a) The synthesis process of the Au@AgBiS2. b–d) TEM images of the Au NRs, Au@ZnO, and Au@AgBiS2. e) HRTEM image of Au@AgBiS2. f–j) STEM images of Au@AgBiS2 and the elemental mappings of S, Bi, Au, and Ag, scale bars for g–j, 50 nm. k) UV–vis‐NIR absorbance spectra of Au, Au@AA‐[Zn(OH)4]2−, Au@ZnS, and Au@AgBiS2. l) XPS of the element peaks of Au@AgBiS2 and m) Bi 4f and S 2p peaks. n) XRD patterns of Au@AgBiS2. o) Zeta potentials and p) size distributions (n = 3) of Au@AgBiS2 and Au@AgBiS2‐PEG as determined by Malvern Zetasizer Nano ZS90.CC BY · PubMed Central
Figure 3 Au@AgBiS2‐PEG augmented RT‐mediate DNA damage and enhanced cancer radiosensitivity via ROS burst. a) Treatment planning for 4T1 cells pretreated with Au@AgBiS2‐PEG combined with RT on DNA damage and repair. 4T1 cells were incubated with PBS, Au or Au@AgBiS2‐PEG and administrated to a single dose of 6 Gy exposure for 1 h and observed with γ‐H2AX and 53BP1 antibodies by immunofluorescence staining after radiotherapy. b,e) γ‐H2AX foci (red) and 53BP1 foci (green) were detected by CLSM in cell nuclei (blue) of 4T1 cells. c,f) The result of γ‐H2AX foci and 53BP1 foci density (γ‐H2AX and 53BP1 foci per cell, n = 50 cells) of 4T1 cells after RT 6 Gy. d,g) The density of γ‐H2AX foci and 53BP1 foci in 4T1 cells at 24 h after 6 Gy exposure. h) Typical images of colony formation of 4T1 cells treated with PBS, Au or Au@AgBiS2‐PEG at various concentrations combined with RT 6 Gy. i) Survival fraction (SF) of 4T1 cells pretreated the different concentrations of PBS, Au or Au@AgBiS2‐PEG under various treatment conditions. j) The SER values of each treatment group were calculated by single‐hit multitarget model (n = 3). k) Generation of ROS within 4T1 cells with different pretreatment by CLSM observation. l) Calculation of mean fluorescence intensity (MFI) of ROS was detected by ImageJ based on DCFH‐DA (green) as probe and DAPI‐labeled cell nuclei (blue) in 4T1 cells (n = 3). Data are indicated as the mean ± SD, and analyzed with one‐way analysis of variance (ANOVA) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
Figure 3 Au@AgBiS2‐PEG augmented RT‐mediate DNA damage and enhanced cancer radiosensitivity via ROS burst. a) Treatment planning for 4T1 cells pretreated with Au@AgBiS2‐PEG combined with RT on DNA damage and repair. 4T1 cells were incubated with PBS, Au or Au@AgBiS2‐PEG and administrated to a single dose of 6 Gy exposure for 1 h and observed with γ‐H2AX and 53BP1 antibodies by immunofluorescence staining after radiotherapy. b,e) γ‐H2AX foci (red) and 53BP1 foci (green) were detected by CLSM in cell nuclei (blue) of 4T1 cells. c,f) The result of γ‐H2AX foci and 53BP1 foci density (γ‐H2AX and 53BP1 foci per cell, n = 50 cells) of 4T1 cells after RT 6 Gy. d,g) The density of γ‐H2AX foci and 53BP1 foci in 4T1 cells at 24 h after 6 Gy exposure. h) Typical images of colony formation of 4T1 cells treated with PBS, Au or Au@AgBiS2‐PEG at various concentrations combined with RT 6 Gy. i) Survival fraction (SF) of 4T1 cells pretreated the different concentrations of PBS, Au or Au@AgBiS2‐PEG under various treatment conditions. j) The SER values of each treatment group were calculated by single‐hit multitarget model (n = 3). k) Generation of ROS within 4T1 cells with different pretreatment by CLSM observation. l) Calculation of mean fluorescence intensity (MFI) of ROS was detected by ImageJ based on DCFH‐DA (green) as probe and DAPI‐labeled cell nuclei (blue) in 4T1 cells (n = 3). Data are indicated as the mean ± SD, and analyzed with one‐way analysis of variance (ANOVA) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).CC BY · PubMed Central
Figure 4 Intracellular cytotoxicity and characterization of the pyroptosis‐inducing performance of Au@AgBiS2‐PEG. a) Relative viability of 4T1 and HC11 cells treated with Au@AgBiS2‐PEG with respective concentrations. b) Release of LDH in 4T1 cells treated with different formulations (n = 3). c) Quantitative analysis of HMGB1 release in 4T1 cells with respective formulations by ELISA (n = 3). d) Representative immunofluorescence images of release of HMGB1 in 4T1 cells with diverse formulations (n = 3). e) Release of ATP in 4T1 cells treated with different formulations (n = 3). f) Quantitative analysis of the percentage of apoptosis cells after various formulations (n = 3). g) A typical apoptosis assay by using AnnexinV‐FITC and PI co‐staining was detected by Flow‐cytometry. h) Western blot analysis of GSDME‐F and GSDME‐N protein expression in 4T1 cells treated with respective formulations. i) Cell morphology images depicting diverse treatments. Cell swelling (red arrow) observed in the Au@AgBiS2‐PEG combined with RT group. Scale bars = 10 µm. Data are indicated as the mean ± SD, and analyzed with one‐way analysis of variance (ANOVA) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
Figure 4 Intracellular cytotoxicity and characterization of the pyroptosis‐inducing performance of Au@AgBiS2‐PEG. a) Relative viability of 4T1 and HC11 cells treated with Au@AgBiS2‐PEG with respective concentrations. b) Release of LDH in 4T1 cells treated with different formulations (n = 3). c) Quantitative analysis of HMGB1 release in 4T1 cells with respective formulations by ELISA (n = 3). d) Representative immunofluorescence images of release of HMGB1 in 4T1 cells with diverse formulations (n = 3). e) Release of ATP in 4T1 cells treated with different formulations (n = 3). f) Quantitative analysis of the percentage of apoptosis cells after various formulations (n = 3). g) A typical apoptosis assay by using AnnexinV‐FITC and PI co‐staining was detected by Flow‐cytometry. h) Western blot analysis of GSDME‐F and GSDME‐N protein expression in 4T1 cells treated with respective formulations. i) Cell morphology images depicting diverse treatments. Cell swelling (red arrow) observed in the Au@AgBiS2‐PEG combined with RT group. Scale bars = 10 µm. Data are indicated as the mean ± SD, and analyzed with one‐way analysis of variance (ANOVA) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).CC BY · PubMed Central
Figure 5 Tumor accumulation study and ROS detection in vivo and performance of antitumor efficacy by Au@AgBiS2‐PEG combined with RT. a) Fluorescence images of 4T1 bearing‐tumors mice intravenously injected with Cy5.5‐labeled Au@AgBiS2‐PEG at various time points (indicated by red dashed circles). b) Quantifications of tumoral mean fluorescence intensity (MFI) of ROS at the respective time points (n = 3). c) Typical images of ROS in tumor slices post different formulations. d) Quantitative analysis of ROS in tumor slices (n = 3). e) Treatment schedule of mice bearing 4T1 tumors treated by Au@AgBiS2‐PEG combined with RT. f) Tumor growth curves of 4T1 bearing‐tumors mice received different formulations (n = 5). g,h) Tumor volume and weight after various treatments. i) The changes of mouse body weight post received various treatments. j) Representative staining images of HMGB1, CRT, and Granzyme B of the tumor tissues. Scale bar is 100 µm (n = 3). Data are indicated as the mean ± SD, and analyzed with one‐way analysis of variance (ANOVA) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
Figure 5 Tumor accumulation study and ROS detection in vivo and performance of antitumor efficacy by Au@AgBiS2‐PEG combined with RT. a) Fluorescence images of 4T1 bearing‐tumors mice intravenously injected with Cy5.5‐labeled Au@AgBiS2‐PEG at various time points (indicated by red dashed circles). b) Quantifications of tumoral mean fluorescence intensity (MFI) of ROS at the respective time points (n = 3). c) Typical images of ROS in tumor slices post different formulations. d) Quantitative analysis of ROS in tumor slices (n = 3). e) Treatment schedule of mice bearing 4T1 tumors treated by Au@AgBiS2‐PEG combined with RT. f) Tumor growth curves of 4T1 bearing‐tumors mice received different formulations (n = 5). g,h) Tumor volume and weight after various treatments. i) The changes of mouse body weight post received various treatments. j) Representative staining images of HMGB1, CRT, and Granzyme B of the tumor tissues. Scale bar is 100 µm (n = 3). Data are indicated as the mean ± SD, and analyzed with one‐way analysis of variance (ANOVA) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).CC BY · PubMed Central
Figure 6 The Au@AgBiS2 combined with RT exhibited an excellent antitumor response in 4T1 tumor models. a) Treatment schedule of 4T1 bearing‐tumor mice treated with various formulations. b,c) Representative flow cytometry plots and analysis of the proportions of mature DCs and effector memory (EM) cells in splenocytes. d,e) Quantitative analysis of the percentages of mature DCs in the splenocytes and TDLN. The proportions of effector memory (EM) cells in CD8+ cells f,g) and CD8+ T cells h,i) in splenocytes and TDLN of mice, respectively. j,k) The concentration of relative cytokines (TNF‐α, IFN‐γ) of serum post various treatments. l) Immunofluorescence staining of cleaved caspase‐3 (c‐Cas‐3) and colocalization of CD4 and CD8 in tumors (n = 3). Data are indicated as the mean ± SD, and analyzed with one‐way analysis of variance (ANOVA) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
Figure 6 The Au@AgBiS2 combined with RT exhibited an excellent antitumor response in 4T1 tumor models. a) Treatment schedule of 4T1 bearing‐tumor mice treated with various formulations. b,c) Representative flow cytometry plots and analysis of the proportions of mature DCs and effector memory (EM) cells in splenocytes. d,e) Quantitative analysis of the percentages of mature DCs in the splenocytes and TDLN. The proportions of effector memory (EM) cells in CD8+ cells f,g) and CD8+ T cells h,i) in splenocytes and TDLN of mice, respectively. j,k) The concentration of relative cytokines (TNF‐α, IFN‐γ) of serum post various treatments. l) Immunofluorescence staining of cleaved caspase‐3 (c‐Cas‐3) and colocalization of CD4 and CD8 in tumors (n = 3). Data are indicated as the mean ± SD, and analyzed with one‐way analysis of variance (ANOVA) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).CC BY · PubMed Central
Figure 7 Au@AgBiS2‐PEG combined with RT‐induced pyroptosis for prevention of tumor metastasis. a) The treatment schedule for mice with different formulations to inhibit tumor metastasis. b) In vivo representative bioluminescence images showing metastatic nodules and the tracking of the spread and growth of intravenously injected 4T1‐luciferase tumor cells in mice on day 10, 15, 20, and 25 according to the treatment schedule. (n = 6). c) Representative photographs of metastatic lung nodules (top) with yellow dashed circles indicating metastatic nodules, and corresponding H&E staining images of metastatic lung nodules (middle and bottom). Scale bar = 100 µm. d) Quantification of metastatic lung nodules after different treatments. (n = 4). e) The proportion of the lung replacement area observed after treatments with various formulations (n = 4). f) Survival analysis of mice treated with different formulations (n = 6). Data are indicated as the mean ± SD, and analyzed with one‐way analysis of variance (ANOVA) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
Figure 7 Au@AgBiS2‐PEG combined with RT‐induced pyroptosis for prevention of tumor metastasis. a) The treatment schedule for mice with different formulations to inhibit tumor metastasis. b) In vivo representative bioluminescence images showing metastatic nodules and the tracking of the spread and growth of intravenously injected 4T1‐luciferase tumor cells in mice on day 10, 15, 20, and 25 according to the treatment schedule. (n = 6). c) Representative photographs of metastatic lung nodules (top) with yellow dashed circles indicating metastatic nodules, and corresponding H&E staining images of metastatic lung nodules (middle and bottom). Scale bar = 100 µm. d) Quantification of metastatic lung nodules after different treatments. (n = 4). e) The proportion of the lung replacement area observed after treatments with various formulations (n = 4). f) Survival analysis of mice treated with different formulations (n = 6). Data are indicated as the mean ± SD, and analyzed with one‐way analysis of variance (ANOVA) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

19 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1002/anie.202204904 · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Xiao, L., Chen, B., Wang, W., Tian, T., Qian, H., Li, X., & Yu, Y.
Affiliations
  • Department of Radiology Research Center of Clinical Medical Imaging Anhui Province Clinical Image Quality Control Center The First Affiliated Hospital of Anhui Medical University Hefei Anhui 230022 P. R. China
  • Anhui Medical University (CN)
  • First Affiliated Hospital of Anhui Medical University (CN)
Corresponding author
  • Qian, Haisheng
  • Li, Xiaohu
  • Yu, Yongqiang
Venue
Advanced Science
Publisher
Wiley
Published
2023-09-08
Volume
10
Issue
30
Pages
e2302141-e2302141
ISSN
2198-3844 (ISSN-L)
OpenAlex
W4386564652
Cited by
64
References
55
Citations by year
2026: 12 · 2025: 25 · 2024: 24 · 2023: 3
FWCI
5.06
Type
journal article
Language
en
Open access
Locations
  • Advanced Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (52172276, U20A20379)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
core-shell nanoparticles, radiosensitizers, radioimmunotherapy, pyroptosis, metal-semiconductor composites, reactive oxygen species, DNA damage, caspase-3 activation, damage-associated molecular patterns, triple-negative breast cancer, lung metastasis, antitumor immunity, gold nanoparticles, silver bismuth sulfide
MeSH terms
Pyroptosis, Animals, Lung Neoplasms, Mice, Inbred BALB C, Radiation-Sensitizing Agents, Radioimmunotherapy, Reactive Oxygen Species, Mice, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.